Get started
Author

Daming Zhu

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
2008 · Yimin Wu, Ruth D. Ellis, et al. · PLoS ONE · 449
PDF
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
2004 · Shobha H. Ganji, S. Tavintharan, et al. · Journal of Lipid Research · 227
Nuclear factor κB is a critical determinant in N‐methyl‐ d ‐aspartate receptor‐mediated neuroprotection
2001 · Robert H. Lipsky, Ke Xu, et al. · Journal of Neurochemistry · 168
CD4+T-Lymphocyte and Immunoglobulin G2 Responses in Calves Immunized withAnaplasma marginaleOuter Membranes and Protected against Homologous Challenge
1998 · Wendy C. Brown, Varda Shkap, et al. · Infection and Immunity · 143
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults
2016 · Kawsar R. Talaat, Ruth D. Ellis, et al. · PLoS ONE · 132
PDF
Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: From genes to phenotype.
2004 · Ann M Marini, Xueying Jiang, et al. · PubMed · 129
Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
2021 · Sara A. Healy, Charles Anderson, et al. · Journal of Clinical Investigation · 107
Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
2008 · Gregory E. D. Mullen, Ruth D. Ellis, et al. · PLoS ONE · 107
PDF
Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
2004 · Aaron P. Miles, Holly A. McClellan, et al. · Vaccine · 99
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
2018 · Issaka Sagara, Sara A Healy, et al. · The Lancet Infectious Diseases · 98
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
2011 · Christopher J. A. Duncan, Susanne H. Sheehy, et al. · PLoS ONE · 96
PDF
AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3‐kinase‐dependent activation in extracellular signal‐regulated kinase to upregulate BDNF gene expression
2004 · Xuan Wu, Daming Zhu, et al. · Journal of Neurochemistry · 92
Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults
2010 · Ruth D. Ellis, Laura B. Martin, et al. · PLoS ONE · 84
PDF
N‐Methyl‐d‐aspartate and TrkB Receptor Activation in Cerebellar Granule Cells
2003 · XUEYING JIANG, DAMING ZHU, et al. · Annals of the New York Academy of Sciences · 80
PDF
The Repertoire ofAnaplasma marginaleAntigens Recognized by CD4+T-Lymphocyte Clones from Protectively Immunized Cattle Is Diverse and Includes Major Surface Protein 2 (MSP-2) and MSP-3
1998 · Wendy C. Brown, Daming Zhu, et al. · Infection and Immunity · 74
PDF
N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway
2005 · Daming Zhu, Xuan Wu, et al. · Journal of Neuroscience Research · 72
A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection
2017 · Prakash Srinivasan, G. Christian Baldeviano, et al. · npj Vaccines · 64
PDF
Highly Conserved Regions of the Immunodominant Major Surface Protein 2 of the Genogroup II Ehrlichial Pathogen Anaplasma marginale Are Rich in Naturally Derived CD4+ T Lymphocyte Epitopes that Elicit Strong Recall Responses
2001 · Wendy C Brown, Travis C McGuire, et al. · The Journal of Immunology · 64
PDF
Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial
2014 · Susanne H Hodgson, Prateek Choudhary, et al. · Molecular Therapy · 58
Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria
2012 · Ruth D. Ellis, Yimin Wu, et al. · PLoS ONE · 53
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial
2023 · Issaka Sagara, Sara A Healy, et al. · The Lancet Infectious Diseases · 50
PDF
Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)
2009 · Daming Zhu, Shuhui Huang, et al. · Journal of Immunological Methods · 43
Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines
2009 · Daming Zhu, Allan Saul, et al. · Vaccine · 40
Differential effects of type I IFNs on the growth of WC1- CD8+ gamma delta T cells and WC1+ CD8- gamma delta T cells in vitro.
1999 · W Tuo, F W Bazer, et al. · PubMed · 38
Differential Effects of Type I IFNs on the Growth of WC1− CD8+ γδ T Cells and WC1+ CD8− γδ T Cells In Vitro
1999 · Wenbin Tuo, Fuller W Bazer, et al. · The Journal of Immunology · 36
Works count: 57
Citation count: 3,000
H-index: 29
I10-index: 42
Year
Topic
Type